Videos

A focused discussion on available treatment options for patients with steroid-refractory cGVHD.

Pashna Munshi, MD reviews risk factors for steroid-refractory cGVHD and the clinical challenges of identification, treatment, and management of the disease.

An overview of common symptoms, diagnostic challenges, and tools for severity assessment of chronic graft-versus-host disease.

Pashna Munshi, MD, discusses the treatment of a 58-year-old man who developed moderate steroid-refractory chronic graft-versus-host disease (cGVHD) after a stem cell transplant, and briefly reviews risk factors for developing cGVHD.

Samuel J. Klempner, MD, discusses unmet needs in patients with gastroesophageal adenocarcinoma when it comes to biomarker-targeted agents.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. An explanation of the role of BCL-2 family proteins in normal cells and in multiple myeloma-affected cells.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Jonathan Kaufman, MD, provides an overview of multiple myeloma, including prevalence and risk populations.

Tracy Rose, MD, discusses the promising outlook of the current bladder cancer space.

Rajneesh Nath, MD, discusses what is in store regarding treatment for elderly patients with relapsed/refractory acute myeloid leukemia.

Srdan Verstovsek, MD, PhD, discusses the tolerability of pacritinib for patients with myelofibrosis.

Closing out their discussion on graft-versus-host disease, participants reflect on patient prognoses and the future directions of care.

A brief discussion on the risk of treatment-induced damage when managing patients with chronic graft-versus-host disease.

Having reviewed approved treatment options for steroid-refractory, chronic GVHD, experts discuss how they would address this patient scenario.

Considerations for belumosudil and axatilimab as treatment options for steroid-refractory chronic graft-versus-host disease.

A review of treatment options approved for steroid-refractory chronic graft-versus-host disease starting with ibrutinib and ruxolitinib.

Shared insight on how to distinguish chronic GVHD from acute GVHD, as well as utilize appropriate methods to risk stratify disease.

Shifting their focus to chronic graft-versus-host disease, experts review a patient scenario and discuss the challenges in early intervention.

Andreana Holowatyj discusses the key takeaway for community oncologists about early-onset appendiceal cancer.

Ravi Salgia, MD, explains how treatment with a tyrosine kinase inhibitor in patients with non–small cell lung cancer can lead to disease transformation.

Ronald L. Paquette, MD, discusses the selection of graft source for bone marrow and stem cell transplants in patients with myelodysplastic syndrome.

Nilanjan Ghosh, MD, PhD, discusses when a Bruton’s tyrosine kinase inhibitor would be preferred over a BCL-2 inhibitor as first-line therapy for patients with chronic lymphocytic leukemia.

Experts review the prognosis of a patient with acute graft-versus-host disease and identify ways to optimize their treatment strategies.

A panel of experts discuss systemic therapy to manage a patient with acute graft-versus-host disease.

Centering discussion on a patient scenario of acute graft-versus-host disease, participants discuss nuance in disease symptomology and patient education.

Eric Nadler, MD, MPP, discusses the design and goals of a retrospective study of real-world adoption of atezolizumab immunotherapy in extensive-stage small cell lung cancer.

Lee Schwartzberg, MD, discusses important questions that have been raised due to the positive results of pembrolizumab immunotherapy for patients with triple-negative breast cancer.

Expert perspectives on the nature and occurrence of graft-versus-host disease alongside available prophylactic regimens.

Jennifer Brown, MD, PhD discusses the purpose of the SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia.

Tycel Phillips, MD, discusses the potential use of glofitamab as therapy for patients with relapsed/refractory mantle cell lymphoma.

Charles Geyer, MD, discusses olaparib for the treatment of patients with BRCA-positive, HER2-negative high-risk early breast cancer as evaluated in the OlympiA study.